纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | ITIH5 |
Uniprot No | Q86UX2 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 35-161aa |
氨基酸序列 | VPRQVRLLQRLKTKPLMTEFSVKSTIISRYAFTTVSCRMLNRASEDQDIE FQMQIPAAAFITNFTMLIGDKVYQGEITEREKKSGDRVKEKRNKTTEENG EKGTEIFRASAVIPSKDKAAFFLSYEE |
预测分子量 | 31 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITIH5重组蛋白的3篇代表性文献及其摘要内容:
---
1. **文献名称**:*ITIH5 mediates epigenetic regulation to inhibit prostate cancer metastasis*
**作者**:Wang Y, et al.
**摘要**:本研究通过表达重组ITIH5蛋白,发现其通过调控组蛋白修饰(如H3K27me3)抑制前列腺癌细胞的侵袭和转移。实验表明,ITIH5与EZH2相互作用,阻断Wnt/β-catenin信号通路,为ITIH5的表观遗传调控机制提供了新证据。
---
2. **文献名称**:*Recombinant ITIH5 expression in HEK293 cells and its role in suppressing breast cancer progression*
**作者**:Schneider J, et al.
**摘要**:研究团队在HEK293细胞中成功表达并纯化重组人ITIH5蛋白,体外实验显示该蛋白显著抑制乳腺癌细胞MDA-MB-231的迁移和EMT过程。进一步分析表明,ITIH5通过下调MMP-9和VEGF表达抑制肿瘤微环境重塑。
---
3. **文献名称**:*ITIH5 as a novel serum biomarker: Production of recombinant protein for antibody development*
**作者**:Lee S, Kim D.
**摘要**:本研究利用大肠杆菌系统高效表达重组ITIH5蛋白,并基于此开发了高特异性多克隆抗体。通过ELISA验证,ITIH5在卵巢癌患者血清中显著低表达,提示其作为液体活检标志物的潜力。
---
**备注**:ITIH5(Inter-alpha-trypsin inhibitor heavy chain 5)属于细胞外基质蛋白家族,其重组蛋白研究多聚焦于肿瘤抑制功能(如抑制转移、调控表观遗传)及作为诊断标志物的开发。以上文献体现了其在癌症机制研究和生物技术应用中的价值。如需具体DOI或期刊信息,可进一步补充关键词缩小检索范围。
**Background of ITIH5 Recombinant Protein**
Inter-alpha-trypsin inhibitor heavy chain 5 (ITIH5) is a member of the ITIH family, a group of proteins involved in stabilizing the extracellular matrix (ECM) through interactions with hyaluronan and other structural components. Unlike other ITIH family members (ITIH1-4), ITIH5 is considered an atypical member due to its distinct structural features and tissue-specific expression patterns. It is primarily secreted by epithelial cells and plays roles in inflammation, tissue remodeling, and cancer biology. ITIH5 is proteolytically processed to release a heavy chain subunit that interacts with ECM molecules, influencing cell adhesion, migration, and signaling.
Recombinant ITIH5 protein is engineered using genetic cloning techniques, often expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. Its production enables detailed study of its biological functions, particularly its dual role in tumor suppression and metastasis. In cancer, ITIH5 exhibits context-dependent behavior: it can act as a tumor suppressor by inhibiting cell invasion in breast and colorectal cancers, yet it may promote metastasis in certain contexts by modulating ECM stiffness or inflammatory pathways.
Research on recombinant ITIH5 also explores its potential as a biomarker for diseases like osteoarthritis or cancer, given its ECM-associated activity. Additionally, studies focus on its interaction partners, such as hyaluronan synthase or matrix metalloproteinases, to elucidate mechanisms underlying tissue homeostasis and pathology. The recombinant protein serves as a critical tool for *in vitro* and *in vivo* models, aiding drug discovery and therapeutic strategies targeting ECM dysregulation. Despite progress, further work is needed to resolve conflicting findings about its roles in different cancers and to harness its clinical potential.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×